I-Mab completes enrollment in Phase 1b dose expansion study for givastomig

I-Mab (IMAB) announced that enrollment in the planned Phase 1b dose expansion cohorts evaluating givastomig, a bispecific Claudin 18.2 x 4-1BB antibody, in combination with nivolumab and mFOLFOX6, has been completed ahead of expectations. The Phase 1b study is evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of givastomig, a Claudin 18.2 x 4-1BB bispecific antibody, used in combination with nivolumab and mFOLFOX6, as first line therapy in patients with CLDN18.2-positive gastric cancers. The study enrolled only patients in the U.S. The dose expansion cohorts of the study enrolled a total of 40 patients across two doses.